From February 28th to March 1st 2019 participants from the 27 partners of the Consortium met during two full days to begin a new adventure.

The meeting took place in Basel, Switzerland, in Novartis premises to lay the foundations of the new IMI2 TransBioLine Project. This is one of the largest public-private partnerships of European and American scientists that focuses on the development and regulatory qualification of new safety biomarkers. The TransBioLine Project provides a unique opportunity to access a large expert and knowledge network, including data and samples from clinical trials, to enable the global safety qualification of identified novel biomarkers.

The meeting achieved the full involvement of the entire consortium to participate in this new challenge